Hem › Hemofili B › Pennsylvania
Kliniska studier för Hemofili B i Pennsylvania
6 studier för Hemofili B söker deltagare vid platser i Pennsylvania.
Städer i Pennsylvania
Officiell studietext (engelska)
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia
- The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia
RekryterarFas 3
Ålder 18 och äldre · Män · Uppdaterad 2 okt. 2026 · NCT05568719A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
- Children's Hospital of Philadelphia (CHOP), Philadelphia
RekryterarFas 1/2
Ålder 2 och äldre · Män · Uppdaterad 11 sep. 2026 · NCT06379789Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- Hemophilia Center of Western Pennsylvania (HCWP), Pittsburgh
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 27 aug. 2026 · NCT06003387ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Children's Hospital of Philadelphia, Philadelphia
- Penn Comprehensive Hemophilia and Thrombophilia Program/Hospital of the University of Pennsylvania, Philadelphia
- St. Christopher's Hospital for Children, Philadelphia
- och 1 fler
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 17 aug. 2026 · NCT04398628A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
- Penn State Milton S Hershey Medical Center Pediatrics, Hershey
- Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program, Philadelphia
RekryterarFas 1Friska volontärer välkomna
Ålder 18 till 60 · Alla kön · Uppdaterad 2 juli 2026 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- The Feinstein Institutes for Medical Research, Philadelphia
RekryterarFas 3
Ålder 1 till 74 · Män · Uppdaterad 1 juli 2026 · NCT05145127Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.